Schlosser Mario 4
4 · Oscar Health, Inc. · Filed Jun 25, 2026
Research Summary
AI-generated summary of this filing
Oscar Health (OSCR) Director Mario Schlosser Sells Shares & Exercises Options
What Happened
- Mario Schlosser, a director of Oscar Health (OSCR), converted derivative securities and exercised stock options on June 23, 2026, then sold shares that same day. He sold a total of 1,027,500 shares in multiple open-market transactions for aggregate proceeds of approximately $30.18 million. Separately, he exercised 660,000 options at $9.75 per share, paying about $6.435 million to acquire those shares.
- The sold shares came from conversions of derivative securities (1,027,500 shares converted) and open-market sales executed at weighted-average prices in the high-$20s to low-$30s. The filing shows the sales were effected under a Rule 10b5-1 trading plan.
Key Details
- Transaction date: June 23, 2026 (Form 4 filed June 25, 2026).
- Sales: 1,027,500 shares sold for total proceeds ≈ $30,183,414 (multiple lots; weighted-average prices reported; price ranges per filing: about $28.08–$30.04).
- Option exercise: 660,000 shares acquired at $9.75 each for $6,435,000 (option fully vested and exercisable; expires Dec 16, 2029).
- Conversions: 1,027,500 shares resulted from conversion of derivative securities (Class B→Class A mechanics noted in filing).
- Plan/notes: Sales effected pursuant to a Rule 10b5-1 plan adopted March 24, 2026 (footnote). Weighted-average price disclosures cover multiple trade prices; full per-price breakdown is available on request per the filing.
- Beneficial ownership: filing disclaims ownership of shares held of record by a trust except to the extent of pecuniary interest (filing footnote).
- Timeliness: Form 4 was filed two days after the transactions (filed 6/25 for transactions on 6/23).
Context
- This was primarily a sale/monetization event (insider sold shares after converting/exercising derivatives). Schlosser paid cash to exercise options (not a cashless exercise). The trades were executed under a pre-established 10b5-1 plan, which is commonly used to schedule sales and reduces questions about opportunistic timing. As always, insider selling is routine and not, by itself, a reliable signal of company prospects.
Insider Transaction Report
Form 4
Schlosser Mario
Director
Transactions
- Conversion
Class A Common Stock
[F1][F2][F3]2026-06-23+880,000→ 1,360,866 total - Sale
Class A Common Stock
[F1][F4][F3]2026-06-23$28.95/sh−286,988$8,308,303→ 1,073,878 total - Sale
Class A Common Stock
[F1][F5][F3]2026-06-23$29.58/sh−591,213$17,488,081→ 482,665 total - Sale
Class A Common Stock
[F1][F3]2026-06-23$30.09/sh−1,799$54,132→ 480,866 total - Conversion
Class A Common Stock
[F1][F2][F6]2026-06-23+50,000→ 50,000 total(indirect: By Trust) - Sale
Class A Common Stock
[F1][F4][F6]2026-06-23$28.95/sh−16,307$472,088→ 33,693 total(indirect: By Trust) - Sale
Class A Common Stock
[F1][F5][F6]2026-06-23$29.58/sh−33,591$993,622→ 102 total(indirect: By Trust) - Sale
Class A Common Stock
[F1][F6]2026-06-23$30.09/sh−102$3,069→ 0 total(indirect: By Trust) - Conversion
Class A Common Stock
[F1][F2][F6]2026-06-23+50,000→ 50,000 total(indirect: By Trust) - Sale
Class A Common Stock
[F1][F4][F6]2026-06-23$28.95/sh−16,306$472,059→ 33,694 total(indirect: By Trust) - Sale
Class A Common Stock
[F1][F5][F6]2026-06-23$29.58/sh−33,592$993,651→ 102 total(indirect: By Trust) - Sale
Class A Common Stock
[F1][F6]2026-06-23$30.09/sh−102$3,069→ 0 total(indirect: By Trust) - Conversion
Class A Common Stock
[F1][F2][F6]2026-06-23+47,500→ 47,500 total(indirect: By Trust) - Sale
Class A Common Stock
[F1][F4][F6]2026-06-23$28.95/sh−15,491$448,464→ 32,009 total(indirect: By Trust) - Sale
Class A Common Stock
[F1][F5][F6]2026-06-23$29.58/sh−31,912$943,957→ 97 total(indirect: By Trust) - Sale
Class A Common Stock
[F1][F6]2026-06-23$30.09/sh−97$2,919→ 0 total(indirect: By Trust) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F7]2026-06-23−660,000→ 3,740,000 totalExercise: $9.75Exp: 2029-12-16→ Class B Common Stock (660,000 underlying) - Exercise/Conversion
Class B Common Stock
[F2][F1]2026-06-23$9.75/sh+660,000$6,435,000→ 2,092,293 total→ Class A Common Stock (660,000 underlying) - Conversion
Class B Common Stock
[F2][F1]2026-06-23−880,000→ 1,212,293 total→ Class A Common Stock (880,000 underlying) - Conversion
Class B Common Stock
[F2][F1][F6]2026-06-23−50,000→ 283,333 total(indirect: By Trust)→ Class A Common Stock (50,000 underlying) - Conversion
Class B Common Stock
[F2][F1][F6]2026-06-23−50,000→ 283,333 total(indirect: By Trust)→ Class A Common Stock (50,000 underlying) - Conversion
Class B Common Stock
[F2][F1][F6]2026-06-23−47,500→ 585,833 total(indirect: By Trust)→ Class A Common Stock (47,500 underlying)
Footnotes (7)
- [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 24, 2026.
- [F2]The Class B common stock is convertible at any time at the option of the holder into Class A common stock on a one-to-one basis, subject to certain exceptions, and will mandatorily convert into Class A common stock on the date that is seven years from the date of the prospectus used in connection with the Issuer's initial public offering and upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation.
- [F3]Includes shares to be issued in connection with the vesting of one or more restricted stock units.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.08 to $29.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.08 to $30.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F6]Mr. Schlosser disclaims beneficial ownership over the shares held of record by the trust except to the extent of his pecuniary interest therein, if any.
- [F7]The stock option is fully vested and exercisable, and expires on December 16, 2029.
Signature
/s/Melissa Curtin, Attorney-in-Fact|2026-06-25